A 12-week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar i disorder suffering from a manic episode

International Clinical Psychopharmacology

Volumn 23, Issue 5, 2008, Pages 254-262

  Bowden, Charles ^a   Göǧüş, Ahmet ^b   Grunze, Heinz ^c   Häggström, Lars ^d   Rybakowski, Janusz ^e   Vieta, Eduard ^f  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d HALMSTAD HOSPITAL   (Sweden)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Acute mania; Bipolar disorder; Clinical trial; Lithium; Valproate

Indexed keywords

DIAZEPAM; LITHIUM; LORAZEPAM; OXAZEPAM; VALPROIC ACID; LITHIUM CARBONATE; TRANQUILIZER;

ADULT; ARTICLE; BIPOLAR I DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; TREMOR; WEIGHT GAIN; YOUNG MANIA RATING SCALE; ADOLESCENT; AGED; BIPOLAR DISORDER; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIMANIC AGENTS; BIPOLAR DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LITHIUM CARBONATE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; VALPROIC ACID;

EID: 54449083711     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3282fd827c     Document Type: Article

References (30)

1. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders. Washington DC: American Psychiatric Association.
2. American Psychiatric Association (2002). Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159:1-50.
3. Bowden CL, Singh V (2005). Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand Suppl 111:13-20.
4. Bowden CL, Calabrese JR, McElroy SL, Gyulai L,Wassef A, Petty F, et al. (2000). A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 57:481-489.
5. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, et al. (2005). A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 66:111-121.
6. Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976). The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33:766-771.
7. Goodwin GM (2003). Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17:149-173; discussion 147.
8. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht RW, et al. (2003). The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry 4:5-13.
9. Hirschfeld R (2002). Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159:1-50.
10. Lambert PA, Carraz G, Borselli S, Carbel S (1966). Action neuro-psychotrope d'un nouvel anti-epileptique: le depamide. (Neuropsychotropic action of a new anti-epileptic agent: depamide). Ann Med Psychol (Paris) 124: 707-710.
11. Macritchie K, Geddes JR, Scott J, Haslam D, de Lima M, Goodwin G (2003). Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev CD004052.
12. Montgomery SA, Åsberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
13. Müller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J (2000). Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol 20:195-203.
14. National Institute for Health and Clinical Excellence (2006). Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. http://www.nice.org.uk/guidance/ cg38/nicegui-dance/pdf/English. Accessed May 2007.
15. Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, et al. (2004). Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 6:213-223.
16. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL (2002). Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 159:1146-1154.
17. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D (2007). Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scand 115:12-20.
18. Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F (2005). Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 15:75-84.
19. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W (1997). Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 73:159-171.
20. Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, et al. (2005). The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 66: 870-886.
21. Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, et al. (2002). Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 159:1011-1017.
22. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, et al. (2003). A 12-week, double-blind comparison of olanzapine vs. haloperidol in the treatment of acute mania. Arch Gen Psychiatry 60:1218-1226.
23. Vieta E (2003). Divalproex versus olanzapine in mania. J Clin Psychiatry 64:1266.
24. Vieta E, Carne X (2005). The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate. Psychother Psychosom 74:10-16.
25. Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, et al. (2005a). Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 187: 235-242.
26. Vieta E, Mullen J, Brecher M, Paulsson B, Jones M (2005b). Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin 21:923-934.
27. Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, et al. (2005). Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 7 (Suppl 3): 5-69.
28. Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, et al. (2006). Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 8:721-739.
29. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429-435.
30. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW (2002). A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 63:1148-1155.